Edition:
United Kingdom

FDA Approves Merck's Keytruda In Combination With Inlyta As First-Line Treatment For Advanced Renal Cell Carcinoma


Monday, 22 Apr 2019 

April 22 (Reuters) - Merck & Co Inc ::FDA APPROVES MERCK’S KEYTRUDA® (PEMBROLIZUMAB) IN COMBINATION WITH INLYTA® (AXITINIB) AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC).MERCK - FDA APPROVES KEYTRUDA (PEMBROLIZUMAB) IN COMBINATION WITH INLYTA AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA.